A recent phase 3 trial showed that for untreated patients with chronic lymphocytic leukemia, measurable residual disease-directed ibrutinib–venetoclax therapy had superior progression-free survival compared...
The FDA approved pirtobrutinib for adults with either chronic lymphocytic leukemia or small lymphocytic lymphoma who have received at least two prior lines of therapy.
A drug that was first approved in 2009 for the treatment of chronic lymphocytic leukemia has now been approved by the FDA to treat relapsing forms of multiple sclerosis.
In a new study that was presented at the 2018 ASCO Annual Meeting, researchers investigated the prevalence of venous thromboembolism in patients with various types of hematologic malignancies, as well as...
In a recent study, researchers evaluated the safety and efficacy of a certain chimeric antigen receptor–modified T cell therapy in patients with chronic lymphocytic leukemia. To see results of the study,...
In the BRUIN CLL-321 trial, pirtobrutinib significantly prolonged progression-free survival and time to next treatment, with fewer grade 3 or higher adverse events than idelalisib plus rituximab or...
A pilot randomized trial found that digital health coaching led to numerical, though not statistically significant, improvements in self-efficacy among patients with newly diagnosed acute myeloid leukemia....
